Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study

被引：0

作者：

Giulia Bon

Laura Pizzuti

Valentina Laquintana

Rossella Loria

Manuela Porru

Caterina Marchiò

Eriseld Krasniqi

Maddalena Barba

Marcello Maugeri-Saccà

Teresa Gamucci

Rossana Berardi

Lorenzo Livi

Corrado Ficorella

Clara Natoli

Enrico Cortesi

Daniele Generali

Nicla La Verde

Alessandra Cassano

Emilio Bria

Luca Moscetti

Andrea Michelotti

Vincenzo Adamo

Claudio Zamagni

Giuseppe Tonini

Giacomo Barchiesi

Marco Mazzotta

Daniele Marinelli

Silverio Tomao

Paolo Marchetti

Maria Rosaria Valerio

Rosanna Mirabelli

Antonio Russo

Maria Agnese Fabbri

Nicola D’Ostilio

Enzo Veltri

Domenico Corsi

Ornella Garrone

Ida Paris

Giuseppina Sarobba

Francesco Giotta

Carlo Garufi

Marina Cazzaniga

Pietro Del Medico

Mario Roselli

Giuseppe Sanguineti

Isabella Sperduti

Anna Sapino

Ruggero De Maria

Carlo Leonetti

Angelo Di Leo

机构：

[1] IRCCS Regina Elena National Cancer Institute,Cellular Network and Molecular Therapeutic Target Unit

[2] IRCCS Regina Elena National Cancer Institute,Division of Medical Oncology 2

[3] IRCCS Regina Elena National CancerInstitute,Pathology Department

[4] IRCCS Regina Elena National Cancer Institute,Area of Translational Research

[5] University of Turin,Department of Medical Sciences

[6] Candiolo Cancer Institute,Medical Oncology

[7] FPO-IRCCS,Radiotherapy Unit, Department of Oncology

[8] Sandro Pertini Hospital,Medical Oncology Unit

[9] Oncology Clinic,Department of Medical, Oral and Biotechnological Sciences

[10] “Ospedali Riuniti di Ancona” Hospital,Department of Medical Oncology

[11] Careggi University Hospital,Oncology Unit, IRCCS Foundation Polyclinic University A. Gemelli

[12] St Salvatore Hospital,Department of Oncology and Hematology

[13] University Gabriele D’Annunzio,Medical Oncology Unit, A.O. Papardo & Department of Human Pathology

[14] University La Sapienza,Medical Oncology Unit, Addarii Institute of Oncology

[15] Breast Cancer Unit,Department of Oncology

[16] ASST Cremona,Medical Oncology Unit

[17] Oncology Unit,Department of Radiological, Oncological and Anatomo

[18] ASST Fatebenefratelli Sacco-PO Fatebenefratelli,Pathological Sciences

[19] University Cattolica Del Sacro Cuore,Medical Oncology

[20] University of Verona,Department of Ematology & Oncology

[21] University Hospital,Medical Oncology Unit

[22] UO Medical Oncology,Medical Oncology Unit

[23] S. Chiara Hospital,Gynaecology – Oncology Unit

[24] University of Messina,Department of Medical Oncology

[25] S. Orsola-Malpighi Hospital,Division of Medical Oncology

[26] University Campus Biomedico,Department of Systems Medicine

[27] Sant’Andrea University Hospital,Radiotherapy Department

[28] University La Sapienza,Department of Medical Oncology

[29] Umberto I University Hospital,Scientific Direction

[30] Paolo Giaccone University Hospital,undefined

[31] Pugliese-Ciaccio Hospital,undefined

[32] Medical Oncology Unit,undefined

[33] Belcolle Hospital,undefined

[34] Medical Oncology Unit,undefined

[35] Lanciano-Vasto,undefined

[36] Santa Maria Goretti Hospital,undefined

[37] Fatebenefratelli Hospital,undefined

[38] Medical Oncology AO S. Croce and Carle Teaching Hospital,undefined

[39] University Cattolica del Sacro Cuore,undefined

[40] Department of Medical Oncology,undefined

[41] ASL Nuro,undefined

[42] IRCCS Giovanni Paolo II,undefined

[43] Division of Medical Oncology,undefined

[44] Pescara Hospital,undefined

[45] Research Unit Phase I Trials and Oncology Unit,undefined

[46] ASST,undefined

[47] Reggio Calabria General Hospital,undefined

[48] Medical Oncology,undefined

[49] University Tor Vergata,undefined

[50] IRCCS Regina Elena National Cancer Institute,undefined

来源：

Journal of Experimental & Clinical Cancer Research | / 39卷

关键词：

HER2+ breast cancer; Trastuzumab/pertuzumab blockade; T-DM1 efficacy;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 50 条

[21] HER2 T cell dependent bispecific antibody (HER2-TDB) for treatment of HER2 positive breast cancer
Junttila, Teemu T.
Li, Ji
Johnston, Jennifer
Hristopoulos, Maria
Clark, Robyn
Ellerman, Diego
Wang, Bu-Er
Li, Yijin
Mathieu, Mary
Li, Guangmin
Young, Judy
Luis, Elizabeth
Phillips, Gail Lewis
Stefanich, Eric
Spiess, Cristoph
Polson, Andrew
Irving, Bryan
Scheer, Justin M.
Junttila, Melissa R.
Dennis, Mark S.
Kelley, Robert
Totpal, Klara
Ebens, Allen
CANCER RESEARCH, 2015, 75
[22] Identifying efficacy of targeted HER2 antibodies in sensitization of HER2 positive breast cancer to fractionated radiation
Song, Patrick N.
Lu, Yun
Napier, Tiara
Samuel, Sharon
Heinzman, Katherine
Lapi, Suzanne E.
Sorace, Anna G.
CANCER RESEARCH, 2021, 81 (04)
[23] TARGETING HER2 WITH TRASTUZUMAB-DM1 (T-DM1) IN HER2-OVEREXPRESSING BLADDER CANCER
Hayashi, Tetsutaro
Jaeger, Wolfgang
Moskalev, Igor
Awrey, Shannon
Li, Na
Fazli, Ladan
Yasui, Wataru
Matsubara, Akio
Black, Peter
JOURNAL OF UROLOGY, 2014, 191 (04): : E301 - E301
[24] Safety and efficacy of T-DM1 in HER2 positive metastatic breast cancer patients: a real word experience
Omarini, C.
Medici, G.
Guaitoli, G.
Iattoni, E.
Moscetti, L.
Balduzzi, S.
Cascinu, S.
Piacentini, F.
ANNALS OF ONCOLOGY, 2016, 27
[25] HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade
Prat, Aleix
Pascual, Tomas
De Angelis, Carmine
Gutierrez, Carolina
Llombart-Cussac, Antonio
Wang, Tao
Cortes, Javier
Rexer, Brent
Pare, Laia
Forero, Andres
Wolff, Antonio C.
Morales, Serafin
Adamo, Barbara
Braso-Maristany, Fara
Vidal, Maria
Veeraraghavan, Jamunarani
Krop, Ian
Galvan, Patricia
Pavlick, Anne C.
Bermejo, Begona
Izquierdo, Miguel
Rodrik-Outmezguine, Vanessa
Reis-Filho, Jorge S.
Hilsenbeck, Susan G.
Oliveira, Mafalda
Vittoria Dieci, Maria
Griguolo, Gaia
Fasani, Roberta
Nuciforo, Paolo
Parker, Joel S.
Conte, PierFranco
Schiff, Rachel
Guarneri, Valentina
Osborne, C. Kent
Rimawi, Mothaffar F.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2020, 112 (01): : 46 - 54
[26] Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade
Fara Brasó-Maristany
Gaia Griguolo
Tomás Pascual
Laia Paré
Paolo Nuciforo
Antonio Llombart-Cussac
Begoña Bermejo
Mafalda Oliveira
Serafín Morales
Noelia Martínez
Maria Vidal
Barbara Adamo
Olga Martínez
Sonia Pernas
Rafael López
Montserrat Muñoz
Núria Chic
Patricia Galván
Isabel Garau
Luis Manso
Jesús Alarcón
Eduardo Martínez
Sara Gregorio
Roger R. Gomis
Patricia Villagrasa
Javier Cortés
Eva Ciruelos
Aleix Prat
Nature Communications, 11
[27] Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade
Braso-Maristany, Fara
Griguolo, Gaia
Pascual, Tomas
Pare, Laia
Nuciforo, Paolo
Llombart-Cussac, Antonio
Bermejo, Begona
Oliveira, Mafalda
Morales, Serafin
Martinez, Noelia
Vidal, Maria
Adamo, Barbara
Martinez, Olga
Pernas, Sonia
Lopez, Rafael
Munoz, Montserrat
Chic, Nuria
Galvan, Patricia
Garau, Isabel
Manso, Luis
Alarcon, Jesus
Martinez, Eduardo
Gregorio, Sara
Gomis, Roger R.
Villagrasa, Patricia
Cortes, Javier
Ciruelos, Eva
Prat, Aleix
NATURE COMMUNICATIONS, 2020, 11 (01)
[28] Dual HER2 Blockade Slows Metastatic Breast Cancer
Bender, Eric
CANCER DISCOVERY, 2012, 2 (01)
[29] Quantification of HER2 autoantibodies in the amplification phenomenon of HER2 in breast cancer
Lauterlein, Jens-Jacob L.
Petersen, Eva R. B.
Olsen, Dorte Aa
Ostergaard, Birthe
Brandslund, Ivan
CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2011, 49 (05) : 877 - 883
[30] Cardiac toxicity in breast cancer patients treated with dual HER2 blockade
Valachis, Antonis
Nearchou, Andreas
Polyzos, Nikolaos P.
Lind, Pehr
INTERNATIONAL JOURNAL OF CANCER, 2013, 133 (09) : 2245 - 2252

← 1 2 3 4 5 →